Comparison of atorvastatin alone versus simvastatin ± cholestyramine in the management of severe primary hypercholesterolaemia (The Six Cities Study)

Australian and New Zealand Journal of Medicine

Volumn 28, Issue 3, 1998, Pages 327-333

  Simons, L A ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Adverse events; Atorvastatin; Efficacy; Hypercholesterolaemia; LDL cholesterol; Randomised trial; Simvastatin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; COLESTYRAMINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; ASTHENIA; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; INSOMNIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY;

EID: 0031876986     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1998.tb01957.x     Document Type: Article

References (25)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. Shepherd J, Cobbe SM, Forde I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
3. Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997; 131: 1-5.
4. Simons LA, Simons J, Parfitt A. Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol. Med J Aust 1992; 157: 455-9.
5. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
6. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-82.
7. Bakker-Arkema RG, Davidson MH, Goldstein RJ et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-33.
8. Allain CC, Poon LC, Chan CSG et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-5.
9. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476-82.
10. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583-95.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the ultracentrifuge. Clin Chem 1972; 18: 449-502.
12. Castelli WP, Anderson K, Wilson PWF, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992; 2: 23-8.
13. Seiler KU, Wolffenbuttel BHR, Mahla D et al. Comparison of atorvastatin, a new HMG-CoA reductase inhibitor, with pravastatin and simvastatin. Atherosclerosis 1994; 109 (special issue): 314 (Abstr. 217).
14. Best JD, Nicholson GC, O'Neal DN et al. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diab Nutr Metab 1996; 9: 74-80.
15. Bertolini S, Bon GB, Campbell LM et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130: 191-7.
16. Simons LA, Nestel PJ, Clifton P et al. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years. Med J Aust 1992; 157: 584-9.
17. Bakker-Arkema RG, Best J, Fayyad R et al. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis 1997; 131: 17-23.
18. Davidson MH, Stein EA, Dujovne CA et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 79: 38-42.
19. Tsalamandris C, Panagiotopoulos S, Sinha A et al. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk 1994; 1: 231-9.
20. Nestel P, Simons L, Barter P et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 1997; 129: 231-9.
21. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5.
22. Alaupovic P, Heinonen T, Shurzinske L, Black DM. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, or lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis 1997; 133: 123-33.
23. Pedersen TR, Kjekshus J, Olsson AG, Cook TJ. 4S results support AHA guidelines to reduce LDL-cholesterol to less than 100 mg/dl in patients with CHD. Circulation 1997; 96:I-717 (Abstr. 4019).
24. Sacks FM, Moye LA, Davis BR et al. The influence on coronary events of lipid therapy during treatment with pravastatin: the CARE trial. Circulation 1997; 96: 1-66 (Abstr. 358).
25. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-82.